Stock LYEL LYELL IMMUNOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
2.43 USD -2.02% Intraday chart for Lyell Immunopharma, Inc. -12.27% +25.26%
May. 06 Sector Update: Health Care Stocks Higher in Late Afternoon Trading MT
May. 06 Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
GL
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
GL
Lyell Immunopharma: Q1 Earnings Snapshot
AQ
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
GL
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
GL
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
GL
Lyell Immunopharma Announces Participation in March Investor Conferences
GL
Lyell Immunopharma Announces Participation in March Investor Conferences
AQ
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
GL
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
GL
Lyell Immunopharma: Q3 Earnings Snapshot
AQ
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
GL
SITC 2023: Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors
PU
SITC 2023: Epi-R P2 protocol produces a scalable polyclonal TIL product with a greater expansion success rate across hot and cold tumors in shorter culture time
PU
SITC 2023: Rejuvenation of tumor-infiltrating lymphocytes (TIL) through Partial Reprogramming
PU
SITC 2023: Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies
PU
SITC 2023: Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors
PU
Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing
GL
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
GL
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LYEL Stock
  4. News Lyell Immunopharma, Inc.
  5. Press Releases